Please login to the form below

Speakers Announced: Maintaining Market Access Continuity through a Global Pandemic Webinar

The global outbreak of coronavirus (COVID-19) and subsequent perception of public health risk creates challenges for international business continuity and market access planning.

In this expert led round table, we bring together key industry stakeholders to share perspectives on some of the implications and consider solutions for how to mitigate the impact on your business at this time of uncertainty.

Key topics will include:

  • Delays to market access planning
  • Market access consequences of sourcing and supply chain issues
  • Delays to day-to-day external engagements
  • Solutions to ensure market access function continuity

This round table brings together leading experts from the pharmaceutical industry, HTA bodies and public health experts to discuss consequences, threats and opportunities, and how to maintain continuity.

The webinar is relevant for market access, pricing, health economics, marketing, commercial and regulatory professionals.

Register your interest here: https://register.gotowebinar.com/register/6893959202322429964

The webinar will be moderated by Raf De Wilde, Senior Executive Advisor at Valid Insight, where he will be joined by expert panellists:

  • Dr. Mathias Flume, Head of Prescription Management at KVWL, Germany
  • Professor Fabrizio Gianfrate, Professor of Health Economics at Rome and Ferrara Universities. Ex-member of the Italian Government Drug Agency (AIFA) and HTA formulary committee and Director at the Ministry of Health
  • Scott Johnstone, CEO of the Scottish Lifesciences Association
  • Sue Caleo-Naeyaert, Senior Advisor Valid Insight, Former Global Head Government Affairs, Policy and Pharmaceconomics at Fresenius Kabi SwissBioSim
  • Professor Jean Paul Stahl, Professor of Infectious Diseases, University Hospital, Grenoble, France. Former President of the French Infectious Diseases Society
  • Edmund Pezalla, Former Vice President, National Medical Director, Pharmaceutical Policy and Strategy at Aetna

Register your interest here: https://register.gotowebinar.com/register/6893959202322429964

17th March 2020

Share

Tags

Company Details

Valid Insight

+44 (0) 20 3750 9833

Contact Website

Address:
152-160 City Road
Kemp House
London
EC1V 2NX
United Kingdom

Latest content on this profile

Last chance to register - Webinar: How to price a pharmaceutical product during a global economic recession
How can you ensure your product achieves optimal market access during a global economic recession?
Valid Insight
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen.
Valid Insight
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative to alternative treatments for successful market access. In this blog, we summarise the reasons for negative reimbursement decisions in 2017 and discuss common pitfalls manufacturers should avoid.
Valid Insight
Using TRAVELLESS™ to provide tailored pharmaceutical training
In May 2020, Valid Insight were scheduled to travel to Grenoble to deliver the market access modules as part of the Advanced Master’s in Biotechnology & Pharmaceutical Management programme with Grenoble Ecole de Management, a French graduate business school. The course has participants from varied backgrounds, but all from roles within the pharmaceutical industry.
Valid Insight
The vicious circle of pharmaceutical tendering
Pharmaceutical tendering and contracting has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s. In the 1990s, international institutions such as the World Health Organisation and the World Bank endorsed tendering as the preferred procurement process for drugs.
Valid Insight
The benefits of a expert-led market access strategy
In order to support effective decision making and deliver sustained returns in a complex, dynamic healthcare environment, pharmaceutical, biotech and medical device companies need an expert-led market access strategy that considers the changing nature of the real-life marketplace. These strategies should not only focus on achieving the commercial objectives for a product but also enable it to outperform competitors throughout the product life cycle.
Valid Insight